Literature DB >> 3832525

Chemotherapy of eyelid and peritorbital tumors.

M N Luxenberg, T H Guthrie.   

Abstract

Eight patients with nine histologically proven BCC or SCC involving the eyelids and periorbital tissues were treated with systemic and/or local (iontophoresis) chemotherapy using cisplatin and doxorubicin. All patients had either refused surgery, would have required extensive procedures, or had medical problems contraindicating surgery. Systemic chemotherapy induced a CR or PR in eight of nine lesions. No patient has required maintenance chemotherapy and no significant toxic side effects were encountered. The length of follow-up ranges from 2 to 50 months. Iontophoretic therapy with cisplatin was used to treat five small foci of new, recurrent or persistent tumor(s) in three of these patients, and resulted in a partial response in all five lesions. Systemic or local chemotherapy offers an alternative to current standard forms of treatment for BCC and SCC in selected cases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3832525      PMCID: PMC1298695     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  14 in total

1.  Cisplatin-associated cortical blindness.

Authors:  C H Pippitt; H B Muss; H D Homesley; V W Jobson
Journal:  Gynecol Oncol       Date:  1981-10       Impact factor: 5.482

2.  Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin.

Authors:  T H Guthrie; E S Porubsky
Journal:  Laryngoscope       Date:  1982-11       Impact factor: 3.325

Review 3.  Eye toxicity of cancer chemotherapy: a review of the literature.

Authors:  J D Griffin; M B Garnick
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

4.  Neurotoxic effects of cisplatin therapy.

Authors:  T J Walsh; A W Clark; I M Parhad; W R Green
Journal:  Arch Neurol       Date:  1982-11

5.  Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II.

Authors:  R Becher; P Schütt; R Osieka; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

6.  Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy.

Authors:  S Ostrow; D Hahn; P H Wiernik; R D Richards
Journal:  Cancer Treat Rep       Date:  1978-10

7.  Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin.

Authors:  T H Guthrie; L J McElveen; E S Porubsky; J D Harmon
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

8.  Cerebral blindness in association with cis-platinum chemotherapy for advanced carcinoma of the fallopian tube.

Authors:  S B Diamond; S H Rudolph; S S Lubicz; G Deppe; C J Cohen
Journal:  Obstet Gynecol       Date:  1982-06       Impact factor: 7.661

9.  Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man.

Authors:  I J Berman; M P Mann
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

10.  Iontophoretic application of idoxuridine for recurrent herpes labialis: report of preliminary clinical trials.

Authors:  L P Gangarosa; H W Merchant; N H Park; J M Hill
Journal:  Methods Find Exp Clin Pharmacol       Date:  1979-06
View more
  2 in total

1.  Cis-platinum chemotherapy for ocular basal cell carcinoma.

Authors:  M Morley; P T Finger; M Perlin; L R Weiselberg; D S DeBlasio
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

2.  Superpulsed CO 2 Laser with Intraoperative Pathologic Assessment for Treatment of Periorbital Basal Cell Carcinoma Involving Eyelash Line.

Authors:  Ali Ebrahimi; Mansour Rezaei; Reza Kavoussi; Mojtaba Eidizadeh; Seyed Hamid Madani; Hossein Kavoussi
Journal:  Dermatol Res Pract       Date:  2014-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.